Form 4: Maravai LifeSciences Director Susannah Gray Awarded Restricted Stock Units

Maravai LifeSciences Holdings, Inc. Director Susannah Gray was granted 89,139 restricted stock units (RSUs) valued at $2.16 per unit, aligning her interests with shareholders.

Summary

• Susannah Gray, a Director of Maravai LifeSciences Holdings, Inc. (MRVI), was awarded 89,139 shares of Class A Common Stock in the form of restricted stock units (RSUs).
• The transaction occurred on June 16, 2025, with a price of $2.16 per share.
• These RSUs were granted under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan.
• The RSUs will vest in full upon the earlier of one year from the grant date (June 16, 2025) or the date of the 2026 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders.
• Following this transaction, Susannah Gray beneficially owns 169,907 shares directly.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the grant of RSUs to a director aligns their interests with shareholders, which is generally viewed favorably. It's a routine compensation event, not indicative of significant operational changes.

Positives

• The grant of restricted stock units to a director aligns management's interests with those of shareholders, as the value of the compensation is tied to the company's stock performance.
• The transaction demonstrates ongoing compensation and retention of key board members.

Future Outlook

The restricted stock units granted to Susannah Gray are set to vest in full upon the earlier of one year from the grant date (June 16, 2025) or the date of the 2026 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders, indicating a future increase in her vested share ownership.

Industry Context

This transaction is a routine insider filing (Form 4) detailing the grant of equity compensation to a director. Such grants are common practice across industries to incentivize and retain key personnel by aligning their financial interests with the long-term performance of the company's stock.

Corporate Governance

Related Party Transactions

• The transaction involves the grant of restricted stock units from Maravai LifeSciences Holdings, Inc. to Susannah Gray, a director of the company, which constitutes a related party transaction.

Stakeholder Impact

• Shareholders: The grant of RSUs may result in minor dilution upon vesting, but it also strengthens the alignment of the director's financial interests with the company's stock performance, potentially benefiting long-term shareholder value.
• Employees/Management: This transaction reflects the company's ongoing compensation strategy for its leadership, which can influence morale and retention.

Next Steps

• The restricted stock units will vest upon the earlier of June 16, 2026, or the date of the 2026 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders.

Key Dates

Keywords

Maravai LifeSciences, MRVI, SEC Form 4, Restricted Stock Units, RSUs, Insider Transaction, Director Compensation, Equity Grant, Stock Ownership, Corporate Governance